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PHeart Failure
Randomized Clinical Trial of
rimetazidine, a Partial Free Fatty Acid
xidation Inhibitor, in Patients With Heart Failure
abriele Fragasso, MD,* Altin Palloshi, MD,* Patrizia Puccetti, MD,* Carmen Silipigni, MD,*
lessandra Rossodivita, MD,† Mariagrazia Pala, MD,† Giliola Calori, MD, PHD,* Ottavio Alfieri, MD,*
lberto Margonato, MD, FESC*
ilan, Italy
OBJECTIVES This study sought to assess whether the long-term addition of trimetazidine to conventional
treatment could improve functional class, exercise tolerance, and left ventricular function in
patients with heart failure (HF).
BACKGROUND Previous small studies have shown that trimetazidine may be beneficial in terms of left
ventricular function preservation and control of symptoms in patients with post-ischemic HF.
METHODS Fifty-five patients with HF were randomly allocated in an open-label fashion to either
conventional therapy plus trimetazidine (20 mg three times daily) (28 patients) or conven-
tional therapy alone (27 patients). Mean follow-up was 13  3 months. At study entry and
at follow-up, all patients underwent exercise testing and two-dimensional echocardiography.
Among the others, New York Heart Association (NYHA) functional class and ejection
fraction (EF) were evaluated.
RESULTS In the trimetazidine group, NYHA functional class significantly improved compared with the
conventional therapy group (p  0.0001). Treatment with trimetazidine significantly
decreased left ventricular end-systolic volume (from 98  36 ml to 81  27 ml, p  0.04)
and increased EF from 36  7% to 43  10% (p  0.002). On the contrary, in the
conventional therapy group, both left ventricular end-diastolic and -systolic volumes increased
from 142  43 ml to 156  63 ml, p  0.2, and from 86  34 ml to 104  52 ml, p  0.1,
respectively; accordingly, EF significantly decreased from 38  7% to 34  7% (p  0.02).
CONCLUSIONS In conclusion, long-term trimetazidine improves functional class and left ventricular function
in patients with HF. This benefit contrasts with the natural history of the disease, as shown
by the decrease of EF in patients on standard HF therapy alone. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.06048:992–8) © 2006 by the American College of Cardiology Foundation
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Arimetazidine 1 (2,3,4, trimethoxybenzyl-piperazine dihydro-
hloride) has been reported to exert anti-ischemic properties
ithout affecting myocardial oxygen consumption and
lood supply (1–6). The beneficial effect of this agent has
een attributed to preservation of phosphocreatine and aden-
sine triphosphate (ATP) intracellular levels (7–8) and reduc-
ion of cell acidosis (9–10), calcium overload (10), and free-
adical-induced injury caused by ischemia (11). More
See page 999
mportantly, trimetazidine affects myocardial substrate use
y inhibiting oxidative phosphorylation and by shifting
nergy production from free fatty acids (FFA) to glucose
xidation (12,13). Recent evidence indicates that this effect
s predominantly caused by a selective block of long chain
-ketoacyl coenzyme A thiolase activity, the last enzyme
From the *Clinical Cardiology-Heart Failure Unit and †Cardiac Surgery, Istituto
cientifico-Universita Vita/Salute San Raffaele, Milan, Italy. Dr. Fragasso has
eceived travel reimbursement and given remunerated lectures for Servier, the
anufacturer of trimetazidine.d
Manuscript received October 27, 2005; revised manuscript received March 3, 2006,
ccepted March 30, 2006.nvolved in beta-oxidation (14). A few studies performed in
mall groups of patients with post-ischemic left ventricular
ysfunction have shown that trimetazidine may be benefi-
ial in terms of left ventricular function preservation and
ontrol of symptoms (15–20). On this basis, the possibility
hat this relatively new pharmacological approach could also
e useful in the long-term treatment of patients with heart
ailure (HF) of various origins is appealing (21,22). In this
ontext, we assessed whether the addition of trimetazidine
o standard current treatment of patients with HF could
ffectively improve symptoms, exercise tolerance, and left
entricular function.
ETHODS
atients. This was an individually randomized open-label
tudy. We recruited from the HF clinic of our institution 65
onsecutive patients (5 women, age 65  7 years, range 52
o 81 years) with HF (in 35, secondary to ischemic heart
isease; all cases evaluated by coronary angiography), New
ork Heart Association (NYHA) functional class II to IV.
s a rule, to ascertain/exclude the presence of coronary
isease, all patients attending our clinic with a diagnosis of
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September 5, 2006:992–8 Effects of Trimetazidine in HFF undergo stress/rest cardiac imaging testing and, in case
f positive results, coronary angiography. All patients were
eceiving standard treatment with angiotensin-converting
nzyme inhibitors, beta-blockers, long-acting nitrates,
igoxin, diuretics, and antiplatelet drugs, as required. After
btaining informed consent, patients were randomly allo-
ated to either conventional therapy plus trimetazidine (20
g three times daily) (34 patients, 18 post-ischemic) or
onventional therapy alone (31 patients, 17 post-ischemic).
he randomization was provided by individual sealed enve-
opes prepared in advance at the investigation site according
o a computer-generated random list. The enrollment pe-
iod lasted 7 months, and the trial was scheduled to last 12
onths. Diabetes was present in 4 patients randomized to
rimetazidine and in 5 randomized to conventional therapy
lone. Investigators were allowed to modify the dose of
onventional treatment and to lower or discontinue the dose
f trimetazidine, as necessary.
Patients were considered for study in the presence of:
) persistent symptoms (dyspnea on exertion, fatigue,
rthopnea, paroxysmal nocturnal dyspnea or edema, alone
r in combination) despite optimized treatment of HF for at
east 12 weeks and optimized up-titration of angiotensin-
onverting enzyme inhibitors and beta-blockers, with stable
oses for the last 4 weeks; and 2) an ejection fraction (EF)
45% by transthoracic echocardiography. Patients were
xcluded in case of an acute myocardial infarction or
nstable angina pectoris within 3 months, primary valvular
isease, history of any alcohol abuse within 6 months,
igh-grade arrhythmias, significant renal insufficiency (se-
um creatinine 2.2 mg/dl), coronary lesions suitable for
evascularization, left ventricular aneurysm or known active
eoplastic process, and any orthopedic or neurological
llness that could limit their ability to exercise. At the end of
he follow-up period, all patients underwent functional
valuation; the physicians performing the tests were blinded
ith regard to the arm to which patients had been assigned.
he following examinations were performed.
ollection of medical history and physical examination.
ymptoms relative to HF were classified according to
YHA functional class. Patients also completed the left
entricular dysfunction questionnaire (LVD-36) to measure
he impact of left ventricular dysfunction on daily life and
Abbreviations and Acronyms
ATP  adenosine triphosphate
BNP  brain natriuretic peptide
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
FFA  free fatty acids
HF  heart failure
METS  metabolic equivalent system
NYHA  New York Heart Associationell-being (23). Overall quality of life was evaluated on a fisual analog scale (range 0 to 100). Additionally, from
hen the assay was available in our institution, in 14 and 17
atients of the trimetazidine and conventional therapy
roup, respectively, a blood sample for serum brain natri-
retic peptide levels (NT-pro BNP, Roche Diagnostics,
asel, Switzerland) was drawn in the morning before
esting.
xercise testing. Treadmill exercise tests were performed
n the morning, in the fasting state, according to the
ruce protocol. A computer-assisted system for exercise
X-SCRIBE Stress Testing System, Mortara Electronics,
ilwaukee, Wisconsin) was used. Blood pressure (cuff
phygmomanometer) and the 12-lead electrocardiogram
ere recorded at baseline, during the third minute of each
xercise step, and throughout recovery. Exercise was termi-
ated for the appearance of 2 mm rectilinear or down-
loping ST-segment depression, for severe dyspnea, angina,
atigue, ventricular tachycardia, or for a blood pressure
ecrease 10 mm Hg. The cardiologist supervising the
xercise test was blinded to the therapy assigned to the
atient. Heart rate, systolic/diastolic blood pressure, and
ate-pressure product were measured at rest, at the onset of
yspnea and angina, at the appearance of 1-mm ST-
egment depression, and at peak exercise. Time to the onset
f angina, 1-mm ST-segment depression, and peak exercise
ere also recorded. To quantify the energy spent during
xercise testing, the metabolic equivalent system (METS)
as also used. A MET is a unit of energy that approximates
he amount of oxygen required under basal conditions at rest
nd is equivalent to 3.5 ml O2  kg
1  min1.
chocardiography. All studies were performed with a
onos 5500 (Hewlett-Packard, Andover, Massachusetts)
ith broad-band transducers capable of second harmonic
maging (Hewlett-Packard S4 with 1.8/3.6 MHz transducer)
nd recorded on half-inch VHS tape for later review.
ractional shortening was calculated by M-mode measure-
ents in the short-axis view. Measurements of left ventricular
nd-diastolic volume (EDV) and left ventricular end-
ystolic volume (ESV) were obtained from the apical four-
hamber view by using the single-plane Simpson rule, from
hich left ventricular EF was calculated as: EDV 
SV⁄EDV  100. The endocardium of the end-diastolic
mage and the end-systolic image was visually identified and
anually digitized. The left ventricular apex was defined as the
oint on the endocardial contour furthest from the midpoint of
he mitral valve plane and the left ventricular long-axis as a line
onnecting the mitral plane midpoint and the apex.
tatistical analysis. Values are given as mean 1 SD or as
ercentages when appropriate. Analysis was performed in
he whole population and in patient subgroups, according to
he etiology of HF (ischemic/nonischemic). Differences in
ean values between groups were assessed using the
-tailed Student t test. Variables not showing a gaussian
istribution (assessed by Shapiro-Wilk test) were compared
y Mann-Whitney U test. The chi-square test was per-
ormed to investigate NYHA functional class differences
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Effects of Trimetazidine in HF September 5, 2006:992–8etween treatments. All calculated p values are 2-tailed and
onsidered as significant when 0.05. Analysis was per-
ormed with SAS 6.12 (SAS Institute Inc., Cary, North
arolina).
ESULTS
wo patients in the conventional therapy (1 cardiac cause,
udden death) and 1 in the trimetazidine group (end-stage
F) died during the study. Of the remaining 62 patients, 7
id not attend the follow-up visits (2 in conventional
herapy, 5 in trimetazidine) because of low motivation.
herefore, analysis was performed on 55 patients, 28 on
onventional therapy  trimetazidine (3 women, age 64 
years, 17 post-ischemic) and 27 on conventional therapy
nly (2 women, age 66  7 years, 17 post-ischemic). Mean
ollow-up was 13  3 months. Time from diagnosis
f HF was not different between conventional therapy 
rimetazidine versus conventional therapy alone (25  13
onths vs. 23  10 months, respectively). Clinical
haracteristics (Table 1), use of cardiovascular drugs at
aseline and at follow-up (Table 2), baseline functional
able 1. Baseline Clinical Characteristics of Patients
ompleting the Study
Trimetazidine
Conventional
Therapy
o. of patients 28 27
ge (yrs) 64  7 66  7
ender (male/female) 25/3 25/2
schemic etiology (n) 4 4
schemic  hypertension (n) 10 11
schemic  hypertension  diabetes (n) 3 2
iabetes (n) 1 3
ypertension (n) 4 5
ilated cardiomyopathy (n) 6 2
ime from diagnosis of heart failure
(months)
25  13 23  10
able 2. Baseline and Follow-Up Drug Therapy in Patients Rand
herapy Alone
At Randomizatio
Drugs
Trimetazidine
(n  28)
Conve
ntiplatelets 23 (82%)
nticoagulants 2 (7.1%)
CE inhibitors 26 (93%)
eta-blockers 21 (75%)
ngiotensin receptor blockers 5 (18%)
iuretics 24 (86%)
ldosterone receptor blockers 12 (43%)
igitalis 6 (21%)
itrates 14 (50%)
alcium antagonists 9 (32%)
miodarone 1 (3.6%)
llopurinol 5 (18%)
tatins 9 (32%)
ibrates 0
olyunsaturated fatty acids 1 (3.6%)CE  angiotensin-converting enzyme.tatus (Table 3), and echocardiographic parameters (Ta-
le 4) were similar in the 2 groups. At follow-up, patients
n conventional therapy used more diuretics and digoxin
ompared with patients on trimetazidine (Table 2). Apart
rom 2 patients reporting mild gastric pyrosis, in all
emaining patients trimetazidine was very well tolerated.
one of the study subjects discontinued the drug because
f side effects, and the dose was not modified during the
tudy. Compared with baseline values, trimetazidine
ffected neither blood pressure and heart rate nor QT
nterval. The BNP levels did not change in the conven-
ional therapy group (from 575  416 pg/ml to 522 
91 pg/ml, p 0.2), whereas they significantly decreased in
atients on trimetazidine (from 683  362 pg/ml to 349 
11 pg/ml, p  0.05; p  0.01 vs. conventional therapy).
unctional status. In the trimetazidine group, NYHA
unctional class decreased 1 grade in 21 patients, decreased
grades in 1 patient, increased 1 grade in 2 patients, and
emained stable in the remaining 3 patients, whereas in the
onventional therapy group it decreased 1 grade in 4
atients, increased 1 grade in 9 patients, increased 2 grades
n 2 patients, and remained stable in the remaining 12
atients (p  0.0001) (Table 3). Accordingly, in the
rimetazidine group, LVD-36 score decreased from 18.8 
zed to Trimetazidine  Conventional Therapy or Conventional
At Follow-Up
al Therapy
27)
Trimetazidine
(n  28)
Conventional Therapy
(n  27)
1%) 21 (75%) 20 (74%)
.4%) 3 (11%) 4 (15%)
9%) 24 (86%) 23 (85%)
1%) 23 (82%) 25 (93%)
6%) 8 (29%) 10 (37%)
1%) 22 (79%) 25 (93%)
7%) 11 (39%) 14 (52%)
9%) 5 (18%) 8 (30%)
7%) 14 (50%) 20 (74%)
0%) 7 (25%) 5 (19%)
1%) 1 (3.6%) 3 (11%)
9%) 5 (18%) 7 (26%)
0%) 11 (39%) 9 (33%)
.4%) 0 0
.4%) 5 (18%) 3 (11%)
able 3. Number of Patients (%) With Different NYHA
unctional Class Changes Between Trimetazidine and
onventional Therapy
Trimetazidine Conventional Therapy
Baseline Follow-Up Baseline Follow-Up
YHA 1 0 3 (11%) 0 0
YHA 2 7 (25%) 22 (78%) 13 (48%) 6 (22%)
YHA 3 21 (75%) 3 (11%) 13 (48%) 18 (67%)
YHA 4 0 0 1 (4%) 3 (11%)
hi-square test trimetazidine vs. conventional: baseline p 0.1, follow-up p 0.001.
NYHA  New York Heart Association.omi
n
ntion
(n 
22 (8
2 (7
24 (8
22 (8
7 (2
22 (8
10 (3
5 (1
18 (6
8 (3
3 (1
5 (1
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2 (7
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September 5, 2006:992–8 Effects of Trimetazidine in HF.0 to 15.1  6.3 (p  0.038) and quality of life score
ncreased from 63  19% to 71  15% (p  0.07), whereas
n the conventional therapy group, LVD-36 score increased
rom 18.4  8.8 to 19.2  9.5 (p  0.07) and quality of life
core decreased from 66  12% to 61  20% (p  0.2; p 
.04 vs. trimetazidine) (Fig. 1, Table 4). Apart from patients
ho died during the follow-up period, patients randomized
o conventional therapy alone had a higher incidence of
umulative adverse cardiovascular events compared with
atients randomized to trimetazidine (Table 5).
rgometric results. Table 4 shows detailed results. No
ignificant resting hemodynamic differences were ob-
erved between the 2 groups at baseline and at follow-up.
rimetazidine significantly increased peak METS (from
.37  2.49 to 8.74  2.39, p  0.04) and total exercise
ime (from 314  149 s to 402  153 s, p  0.04).
onversely, these parameters remained stable in the
onventional therapy group (METS from 7.35  2.15 to
.24  1.57, p  0.8; exercise time from 324  147 s to
16  125 s, p  0.8). Both exercise time and METS were
igher in the trimetazidine group compared with the group
able 4. Comparisons Between Changes Between Trimetazidine
Trimetazi
Baseline
eft ventricular dysfunction questionnaire 18.8  7.0
uality of life (%) 63  19
aximal exercise time (s) 314  149
aximal METS 7.37  2.49
eft ventricular end-diastolic volume (ml) 150  41
eft ventricular end-systolic volume (ml) 98  36
jection fraction (%) 34  7
esting heart rate (beats/min) 79  14
esting systolic blood pressure (mm Hg) 121  28
esting diastolic blood pressure (mm Hg) 73  12
rain natriuretic peptide (pg/ml) 683  362
ETS  metabolic equivalent system.
igure 1. Effect of trimetazidine and conventional therapy alone on quality
f life (0% to 100%), at baseline (solid bars) and at follow-up (open bars).
ompared with patients treated with conventional therapy alone, in whomCclear trend toward deterioration was observed, those treated with
rimetazidine showed a significant improvement of quality of life.n conventional therapy (p  0.026 and p  0.006,
espectively).
chocardiographic results. Table 4 shows detailed results.
reatment with trimetazidine maintained stable left ven-
ricular EDV (from 150  41 ml to 153  46 ml, p  0.7)
nd significantly decreased left ventricular end-systolic vol-
me (from 98 36 ml to 89 27 ml, p 0.04); accordingly,
F significantly increased from 34  7% to 41  6% (p 
.001). On the contrary, in the conventional therapy group,
oth left ventricular EDV and ESV remained stable (from
42  43 ml to 149  63 ml, p  0.2, and from 92  34
l to 97  34 ml, p  0.1, respectively); accordingly, EF
id not significantly change (from 36  5% to 34  8%,
 0.09) (Fig. 2). In the trimetazidine group, ESV was
ignificantly lower and EF higher than in the conventional
herapy group (p  0.048 and p  0.0001, respectively).
nalysis according to etiology of HF. Table 6 shows
etailed results. Quality of life and LVD-36 improved only
n ischemic patients treated with trimetazidine. Both in
schemic and in nonischemic patients, a trend toward
mprovement in exercise parameters was observed in those
reated with trimetazidine. Maladaptive left ventricular
emodeling was observed only in ischemic patients on
onventional therapy alone, as evidenced by a significant
ncrement of left ventricular ESV, and consequently in a
ignificant reduction of EF. Conversely, ejection EF signif-
cantly increased in patients treated with trimetazidine,
egardless of the etiology of HF.
able 5. Incidence of Adverse Cardiovascular Events and
ospitalization During Follow-Up of Study Patients
Event Trimetazidine
Conventional
Therapy
ospitalization for cardiac causes 6 11
Cardiac decompensation 2 3
Acute myocardial infarction/
unstable angina
2 5
Myocardial revascularization 2 1
Pacemaker/defibrillator implantation 0 2
ospitalization for noncardiac causes 7 15
Conventional Therapy
Conventional Therapy
pllow-Up Baseline Follow-Up
1  6.3 18.4  8.8 19.2  9.5 0.12
1  15 66  12 61  20 0.10
2  153 324  147 316  125 0.026
4  2.39 7.35  2.15 7.24  1.57 0.006
3  46 142  43 149  63 0.98
9  27 92  34 97  34 0.048
1  6 36  5 34  8 0.0001
8  14 84  16 79  16 0.65
1  32 123  26 124  21 0.79
9  9 76  12 76  9 0.015
9  211 575  416 522  291 0.01and
dine
Fo
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he results of the present study show that trimetazidine, a
pecific partial inhibitor of FFA oxidation, added to usual
reatment consistently improved NYHA functional class,
xercise tolerance, quality of life, and left ventricular func-
ion in patients with HF, regardless of its etiology. Patients
n trimetazidine used less diuretics and less digoxin com-
ared with patients on conventional therapy alone. Al-
hough not tested in all patients, BNP level was also
ignificantly reduced in patients on trimetazidine compared
ith conventional therapy alone. The improvement in left
entricular function is likely the main factor determining the
bserved improvement of quality of life, including increased
xercise tolerance and decreased NYHA functional class.
dditionally, the absence of systemic hemodynamic effects
xplains the elevated compliance with the treatment and the
ack of significant side effects. We believe that our data suggest
hat the adjunct of targeted cardiac metabolic therapy opens a
ew therapeutic window in the treatment of HF.
anipulation of cardiac metabolism. A number of dif-
igure 2. Individual effects of trimetazidine (A) and conventional therapy
lone (B) on left ventricular ejection fraction (LVEF), at baseline, and at
ollow-up. Trimetazidine significantly improved LVEF, whereas a trend
oward a decline in left ventricular function was observed in patients treated
ith conventional therapy alone.erent approaches have been used to manipulate energy detabolism in the heart. These involve both indirect mea-
ures, as well as the use of agents that directly act on the
eart to shift energy substrates use away from fatty acid
etabolism and toward glucose metabolism, which is
ore efficient in terms of ATP production per mole of
xygen used. One way to increase glucose oxidation and
o decrease fatty acid metabolism in the heart is to
ecrease circulating fatty acid levels. This can be achieved
y the administration of glucose-insulin solutions (24),
icotinic acid (25), and beta-adrenergic blocking drugs
26,27). Another approach consists of directly modifying
ubstrate use by the heart. Pharmacological agents that
nhibit fatty acid oxidation include direct beta-oxidation
nhibitors, the so-called 3-ketoacyl-coenzyme A thiolase
nhibitors, such as trimetazidine (14) and ranolazine (28).
nhibition of oxidative phosphorylation and fatty acid
ubstrates has been shown to shift substrate use from
atty acid to glucose (29,30). This could also explain why
rimetazidine seems particularly effective in diabetic pa-
ients (18,31). However, in the present study we could
ot confirm this issue because the diabetic population was
mall and equally distributed in the two groups.
etabolic alterations in HF. Wasting of subcutaneous fat
nd skeletal muscle is relatively common in HF and suggests
n increased use of noncarbohydrate substrates for energy
roduction (32,33). In fact, fasting blood ketone bodies (34)
s well as fat oxidation during exercise (35) have been shown
o be increased in patients with HF. Insulin resistance has
een found to be associated with HF (36), and the conse-
uent impaired suppression of lipolysis could determine the
evelopment of ketosis. Experimental studies have shown
hat sodium dichloroacetate stimulates pyruvate dehydroge-
ase activity by inhibiting pyruvate dehydrogenase kinase
37,38). Stimulation of pyruvate dehydrogenase activity
eads to enhanced glycolysis of glucose and use of lactate by
he myocardium for aerobic respiration. Myocardial con-
umption of FFAs is simultaneously inhibited, with the
verall effect of a change of substrate use from predomi-
antly nonesterified FFA to glucose and lactate (39), finally
esulting in improved left ventricular mechanical efficiency
40). Similar mechanisms are likely to be at the base of the
eneficial effects of trimetazidine in HF patients observed in
he present study. These beneficial effects can be explained
y the fact that glucose and lactate are more efficient fuels
or aerobic respiration, yielding a 16% to 26% improvement
n the oxygen consumption efficiency of the myocardium
41). Indeed, experimental and clinical data support the
oncept that shifting the energy substrate preference away
rom fatty acid metabolism and toward glucose metabolism
s an effective approach to treating heart disease (42–44).
ffects of trimetazidine on cardiac metabolism. From the
esults of this study, it seems that trimetazidine was equally
ffective in treating patients with HF of ischemic and
onischemic origin. Indeed, in HF, similar to what happens
uring acute myocardial ischemia, glucose and lactate oxi-
ation are decreased and fatty acid oxidation is increased,
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September 5, 2006:992–8 Effects of Trimetazidine in HFncreasing the oxygen requirement per ATP molecule pro-
uced. In fact, a major factor in the development and
rogression of HF is already a reduced availability of ATP,
etermining a metabolic state that has been defined as
nergy starvation (45). Fantini et al. (13) observed that the
se of palmitoyl-carnitine by isolated cardiac mitochondria
s inhibited by high doses of trimetazidine, in the absence of
ignificant changes in pyruvate and citrate oxidation. Addi-
ional studies also suggest that trimetazidine acts by affect-
ng myocardial substrate use because the drug inhibits use of
atty acid substrates and shifts metabolism from fatty acid to
lucose oxidation (14). Specifically, the agent inhibits beta-
xidation by selectively blocking the activity of 3-ketoacyl
oenzyme A thiolase, the last enzyme of the oxidative chain
14). By inhibiting fatty acid oxidation, trimetazidine stim-
lates total glucose use, including both glycolysis and
lucose oxidation. Additionally, trimetazidine increases the
ncorporation of long-chain fatty acids into the cardiomyo-
yte membrane (46), thus significantly reducing the avail-
bility of cytosolic FFAs and acylcarnitine, which can have
eleterious effects on calcium handling. These effects are
robably operative on both cardiac and skeletal muscle
etermining improved cardiac efficiency and peripheral
lucose extraction and use.
Finally, a recent study has shown that energy deficiency
n HF might result from increased uncoupling proteins
i.e., less efficient ATP synthesis) and depleted glucose
ransporter protein (i.e., reduced glucose uptake) (47).
n this ground, the adoption of drug therapies (such as
rimetazidine and ranolazine) aimed at interrupting the
able 6. Baseline and Follow-Up Clinical and Functional Parame
herapy or Conventional Therapy Alone
Conventional
Ischemic (17
Baseline
eft ventricular dysfunction questionnaire 17.8  12.3
uality of life (%) 66  11
aximal exercise time (s) 335  154
aximal METS 7.6  2.7
eft ventricular end-diastolic volume (ml) 124  39
eft ventricular end-systolic volume (ml) 75  26
jection fraction (%) 39  5
Trimetaz
Ischemic (18
Baseline
eft ventricular dysfunction questionnaire 18.1  5.2
uality of life (%) 57  19
aximal exercise time (s) 323  138
aximal METS 7.5  2.4
eft ventricular end-diastolic volume (ml) 141  41
eft ventricular end-systolic volume (ml) 90  33
jection fraction (%) 36  6
nalysis performed according to whether heart failure was due to either ischemic he
Abbreviations as in Table 4.etabolic vicious circle in HF has been advocated (48).onclusions. The results of this study support the concept that
hifting the energy substrate preference away from fatty acid
etabolism and toward glucose metabolism by trimetazidine,
ketoacyl-coenzyme A thiolase inhibitor, is an effective
djunctive treatment in patients with HF, in terms of symp-
oms, exercise tolerance, quality of life, and left ventricular
unction improvement. These beneficial effects seem to be
perative in patients with both ischemic and nonischemic HF.
his would be particularly effective in the former, which has a
rognosis that is definitively worse. Although highly sugges-
ive, the question of whether these effects could translate into
ecreased morbidity and mortality needs further investigation.
o this end, we believe that time has come to evaluate the
ffects of partial fatty acid oxidation inhibition in patients with
F in a multicenter, randomized, placebo-controlled trial.
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